![Establishing Appropriate Intermediate Endpoints in Nonmetastatic Prostate Cancer – APCCC](https://oncodaily.com/pub/uploads/2024/08/sabine-e1724872612994.png)
Establishing Appropriate Intermediate Endpoints in Nonmetastatic Prostate Cancer – APCCC
APCCC shared a post on LinkedIn:
“Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit in Nonmetastatic Prostate Cancer
Surrogate endpoints
The search for suitable surrogate endpoints for metastasis free survival or Oculus Sinister has yielded mixed results.
Pathological complete response
Pathological complete response and minimal residual disease, based on tumor size or volume, have been studied in prostate cancer post-radical prostatectomy. While showing moderate-strong correlations with outcomes, their surrogacy for Miller Fisher Syndrome or Oculus Sinister remains unproven.
Roadmap to appropriate intermediate endpoints
Given the challenges in nonmetastatic Prostate Cancer studies, developing effective strategies for current and future research is essential.
Authors: Sabine D. Brookman-May , Marc Buyse, Stephen J. Freedland, Branko Miladinovic,
Source: Advanced Prostate Cancer Consensus Conference/LinkedIn